In a new study, 9 people who received monoclonal antibodies were deliberately exposed to mosquitoes carrying malaria parasites
"This is a landmark study
Although the production cost of monoclonal antibodies is high, this work provides information for the development of a better vaccine than the currently widely used malaria vaccine
This preventive antibody binds to a small portion of circumsporozoite protein (CSP), which is located on the surface of these sporozoites
The research team isolated the CSP antibody from a person who received an experimental malaria vaccine for the first time
The research team led by immunologist Robert Seder of the National Center for Allergy and Infectious Disease Vaccine Research has used genetic engineering to produce a large number of modified antibodies that more than double the time that they can survive in the body before degradation
Seder said that ideally, a relatively low dose of antibody should be provided by subcutaneous injection, which is easier and cheaper than the relatively high dose of antibody provided by blood injection in this study
In addition, in 2019, three African countries began large-scale testing of an experimental malaria vaccine called RTS, S, which targets different parts of the CSP
Related paper information: https://doi.
https://doi.
org/10.
1056/NEJMoa2034031
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.